Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic…
Big Pharma loves political gridlock. In fact, shares of pharmaceutical and biotechnology companies tend to outperform the broader market when Congress is divided.…
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR…
Regeneron Pharmaceuticals is developing new antibodies that work against the omicron variant of Covid-19, after the company confirmed that its current cocktail has diminished potency against…
Regeneron said on Tuesday that its Covid-19 antibody treatment might be less effective against the Omicron variant of the coronavirus, an indication that the popular and widely beneficial…
Early testing indicates that the mutations in the Omicron variant of coronavirus may hamper the ability of Regeneron’s antibody drug to treat Covid-19, the company said, indicating…
You're reading Entrepreneur United States, an international franchise of Entrepreneur Media.
This story originally appeared on The Epoch Times
Monoclonal antibodies…
Dr. Leonard Schleifer, CEO, RegeneronScott Mlyn | CNBCRegeneron's monoclonal antibodies grant months of protection from Covid-19 and could be administered to individuals whose immune systems…